263 related articles for article (PubMed ID: 27435856)
1. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy.
Zhu S; Wu Y; Ye X; Ma L; Qi J; Yu D; Wei Y; Lin G; Ren G; Li D
Mol Cell Biochem; 2016 Sep; 420(1-2):107-19. PubMed ID: 27435856
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effect of fibroblast growth factor 21 on NAFLD in MSG-iR mice and its mechanism].
Zhu SL; Zhang ZY; Ren GP; Ye XL; Ma L; Yu D; Han MM; Zhao JZ; Zhang TY; Li DS
Yao Xue Xue Bao; 2013 Dec; 48(12):1778-84. PubMed ID: 24689234
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
4. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
5. Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.
Wu YK; Ren ZN; Zhu SL; Wu YZ; Wang G; Zhang H; Chen W; He Z; Ye XL; Zhai QX
Acta Pharmacol Sin; 2022 Jun; 43(6):1473-1483. PubMed ID: 34654875
[TBL] [Abstract][Full Text] [Related]
6. A Fibroblast Growth Factor 21-Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease.
Woolsey SJ; Beaton MD; Mansell SE; Leon-Ponte M; Yu J; Pin CL; Adams PC; Kim RB; Tirona RG
Mol Pharmacol; 2016 Oct; 90(4):437-46. PubMed ID: 27482056
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
[TBL] [Abstract][Full Text] [Related]
8. Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats.
Wang WF; Li SM; Ren GP; Zheng W; Lu YJ; Yu YH; Xu WJ; Li TH; Zhou LH; Liu Y; Li DS
Endocrine; 2015 May; 49(1):119-29. PubMed ID: 25306889
[TBL] [Abstract][Full Text] [Related]
9. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
Chang E; Kim L; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park CY
World J Gastroenterol; 2015 Jul; 21(25):7754-63. PubMed ID: 26167075
[TBL] [Abstract][Full Text] [Related]
10. Akebia Saponin D Decreases Hepatic Steatosis through Autophagy Modulation.
Gong LL; Li GR; Zhang W; Liu H; Lv YL; Han FF; Wan ZR; Shi MB; Liu LH
J Pharmacol Exp Ther; 2016 Dec; 359(3):392-400. PubMed ID: 27672081
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress.
Kim SH; Kim KH; Kim HK; Kim MJ; Back SH; Konishi M; Itoh N; Lee MS
Diabetologia; 2015 Apr; 58(4):809-18. PubMed ID: 25537833
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway.
Zhang Y; Chen ML; Zhou Y; Yi L; Gao YX; Ran L; Chen SH; Zhang T; Zhou X; Zou D; Wu B; Wu Y; Chang H; Zhu JD; Zhang QY; Mi MT
Mol Nutr Food Res; 2015 Aug; 59(8):1443-57. PubMed ID: 25943029
[TBL] [Abstract][Full Text] [Related]
13. FGF21 treatment ameliorates alcoholic fatty liver through activation of AMPK-SIRT1 pathway.
Zhu S; Ma L; Wu Y; Ye X; Zhang T; Zhang Q; Rasoul LM; Liu Y; Guo M; Zhou B; Ren G; Li D
Acta Biochim Biophys Sin (Shanghai); 2014 Dec; 46(12):1041-8. PubMed ID: 25355486
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice.
Rusli F; Deelen J; Andriyani E; Boekschoten MV; Lute C; van den Akker EB; Müller M; Beekman M; Steegenga WT
Sci Rep; 2016 Jul; 6():30484. PubMed ID: 27470139
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of sterol regulatory element binding protein‑2 alleviates autophagic dysfunction in NAFLD.
Cheng C; Deng X; Xu K
Int J Mol Med; 2018 Apr; 41(4):1877-1886. PubMed ID: 29336468
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JNK suppresses autophagy and attenuates insulin resistance in a rat model of nonalcoholic fatty liver disease.
Yan H; Gao Y; Zhang Y
Mol Med Rep; 2017 Jan; 15(1):180-186. PubMed ID: 27909723
[TBL] [Abstract][Full Text] [Related]
17. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
Liu J; Xu Y; Hu Y; Wang G
Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Growth Factor 21 Stimulates Pancreatic Islet Autophagy via Inhibition of AMPK-mTOR Signaling.
Cheng STW; Li SYT; Leung PS
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31121855
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
Tucker B; Li H; Long X; Rye KA; Ong KL
Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
[TBL] [Abstract][Full Text] [Related]
20.
Long X; Liu D; Gao Q; Ni J; Qian L; Ni Y; Fang Q; Jia W; Li H
Front Endocrinol (Lausanne); 2021; 12():773340. PubMed ID: 35035378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
